Skip to content
Peptide Atlas
All goals

Peptides studied for mental clarity and long-term brain protection

Several of these compounds are studied for whether they can support the brain's own growth signals and the chemistry behind attention and memory. Two animal-brain extracts (Cerebrolysin and Cortexin) have human trial data, mostly in people with existing brain injury or dementia rather than healthy adults. The rest rest largely on animal, laboratory, or observational evidence, and none is shown to prevent decline in a healthy brain.

The biology of this goal

The brain keeps its nerve cells alive and connected using natural 'growth signal' molecules — proteins like BDNF and NGF that tell neurons to survive, grow, and form new links with each other. Attention, motivation and mood also depend on chemical messengers such as dopamine and serotonin that carry signals between cells. When the brain is injured, starved of oxygen, or ageing, these growth signals weaken, harmful inflammation and free radicals build up, and connections are lost. The compounds here are being studied for whether they can boost those growth signals, calm the damage, and help neurons build new connections.

What the research supports

6 of 9 relevant, from 17 considered

Cerebrolysin

Tier 1 · Human trials

Human trials and meta-analyses report modest cognitive benefit in dementia and other clinical populations, though rigorous reviewers note the evidence remains inconsistent.

Cerebrolysin is a liquid made from pig brain tissue broken down into free amino acids and small peptides that behave like the body's own nerve-growth signals. It is given by injection because peptides are destroyed in the gut. It is studied for whether it can help neurons survive and form new connections, and for improving memory and thinking.

  • A meta-analysis of six randomized controlled trials (597 participants) found benefit on general cognition (MMSE weighted mean difference 1.10, 95% CI 0.37 to 1.82) and on ADAS-cog+ (WMD -4.01, 95% CI -5.36 to -2.66) in mild-to-moderate vascular dementia.2

  • In a randomized controlled trial in infants with severe perinatal brain insult, the Cerebrolysin group showed large gains from baseline at three months in social (65.44%), speech (45.54%), symbolic (358.06%) and total (96.00%) communication scores (p<0.001).1

  • It is approved in many European and Asian countries for stroke, traumatic brain injury and dementia but not by the U.S. FDA, and whether it prevents dementia or slows cognitive decline remains unknown.3

  • Small trials reported improved cognition and memory in schizophrenia patients and improved memory (but not verbal fluency) in older adults with memory loss, with effects on memory lower than approved Alzheimer's drugs.3

What this doesn't establish

No study has tested whether it prevents dementia or slows decline in healthy adults, and one uncontrolled healthy-elderly result may have been placebo effect; its memory effect was smaller than approved Alzheimer's drugs.

Cortexin

Tier 1 · Human trials

Human trials — largely in Russian clinical populations — report improvements in concentration, memory and cognition, though independent reviewers judge the human evidence weak.

Cortexin is a mixture of small peptides extracted from the brain cortex of young cattle and pigs, given by injection. It is proposed to protect neurons broadly and to support the chemical messengers behind attention and memory. It is used in Russia and neighbouring countries for cognitive and developmental problems.

  • A multicenter study of 635 children aged 3–7 across four clinical groups (ADHD, speech delay, perinatal CNS lesion, asthenic/neurotic syndrome) reported a reliable effect on cognitive impairment after 10 intramuscular injections.4

  • In post-Covid cognitive impairment (109 patients, ages 42–65), Cortexin at 10 mg intramuscularly for 20 days improved concentration and control of executive functions (p<0.05) and auditory-verbal memory (p=0.002), with no adverse events reported.5

  • In rat models of developmental delay, Cortexin decreased structural changes in brain tissue.6

  • Experimental studies showed the ability to modulate dopamine content in the brain, and components interact with neuron-specific β5-tubulins.4

What this doesn't establish

The trials are in impaired or developmentally delayed populations rather than healthy adults seeking sharper focus, and the dopamine-modulating claim rests on experimental rather than human data.

Semax

Tier 2 · Preclinical

Animal and laboratory studies suggest nootropic and neuroprotective effects, with some human data reporting improved short-term memory, but the evidence base is early.

Semax is a lab-made short peptide based on a fragment of the hormone ACTH, designed to keep its brain-supporting effects without the hormonal stress action. In animals it raises the brain's growth factors and nudges dopamine and serotonin signalling. It has been studied as a nootropic — a memory- and attention-enhancing agent — and for stroke recovery.

  • Semax increases expression of neurotrophins such as BDNF and TrkB in the hippocampus and ischemic brain tissue.7

  • In healthy volunteers, intranasal Semax improved operative (working) memory.7

  • In mice, Semax and a derivative improved cognitive function across open field, novel object recognition and Barnes maze tests.8

  • In rats, Semax reduced anxiety-like behaviour and normalized brain biogenic amine levels disrupted by early-life fluvoxamine exposure.9

What this doesn't establish

The strongest cognitive results come from rodent models and small volunteer studies, not large controlled trials in healthy people pursuing everyday focus.

Noopept

Tier 2 · Preclinical

It is used in Europe for mild cognitive decline and human comparative trials exist, but much of the mechanistic and pharmacokinetic detail comes from animal and cell studies.

Noopept is a synthetic two-amino-acid compound related to piracetam and based on a natural brain peptide. It is broken down quickly and works mainly as a prodrug — the body converts it into cycloprolylglycine, which is thought to carry the lasting effect. It is studied for raising the brain's growth factors and supporting memory and attention.

  • Noopept is a synthetic dipeptide that can enhance BDNF and NGF in the brain, is used in Europe to treat mild cognitive decline, and penetrates the blood-brain barrier when taken orally.10

  • It has been characterized as increasing cognitive function in cell culture and in-vivo models of brain-degenerative disease, including by clearing protein aggregates from brain tissue.10

  • Metabolism studies found the parent compound undetectable in rat brain one hour after 5 mg/kg dosing while cyclo-prolylglycine rose 2.5-fold, indicating Noopept acts as a prodrug for this endogenous nootropic cyclopeptide.12

  • After oral dosing in rats, brain and serum concentrations were similar, indicating easy blood-brain-barrier crossing, and cycloprolylglycine rose 2.4-fold in neural tissue after injection.11

What this doesn't establish

The neurotrophic and cognitive claims rest largely on cell-culture and rodent models plus Russian clinical data; robust trials in healthy people are lacking.

Selank

Tier 2 · Preclinical

A human trial reports anxiolytic effects comparable to a benzodiazepine, while its nootropic and neurochemical mechanisms are supported mainly by animal studies.

Selank is a lab-made seven-amino-acid peptide built from tuftsin, a natural immune-signalling fragment. It is described as calming and memory-supporting, working indirectly on the brain's main calming system rather than binding the same site as Valium-type drugs. It is relevant here for supporting growth factors and balancing dopamine and serotonin activity.

  • In patients with generalized anxiety disorder and neurasthenia (62 total; 30 on Selank), Selank showed anxiolytic effects similar to medazepam, with reduced leu-enkephalin half-life correlating with symptom severity.13

  • In rats, individual Selank administration was most effective at reducing elevated anxiety, while combined with diazepam it was most effective under unpredictable chronic mild stress.14

  • Under social stress in rats, Selank decreased pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, along with TGF-β1, toward control values.15

What this doesn't establish

The human data centre on anxiety in patients with GAD and neurasthenia rather than on measurable focus or clarity gains, and the BDNF and dopamine claims come from animal or mechanistic reports.

Dihexa

Tier 3 · Reported use

Animal and laboratory studies suggest it builds new synapses and improves memory, but there are no human trials and some foundational papers have been retracted for data problems.

Dihexa is a synthetic peptide derived from angiotensin IV and stabilized to survive in the body. Instead of acting on classic receptors, it boosts the activity of hepatocyte growth factor (HGF), a signal that drives brain cells to build new connections. In animals this is linked to better learning and memory, and it can be taken by mouth and reach the brain.

  • Dihexa induces dendritic arborization and synaptogenesis by stimulating the HGF/c-Met system and has facilitated new functional synaptic connections and memory consolidation in animal models of Alzheimer's disease.19

  • In APP/PS1 mice, orally administered Dihexa crossed the blood-brain barrier and restored spatial learning and cognitive function on the Morris water maze via PI3K/AKT signalling.20

  • It is a metabolically stable, blood-brain-barrier-permeable angiotensin IV analogue that shows promise for memory and motor dysfunction by augmenting synaptic connectivity.21

What this doesn't establish

All efficacy evidence is preclinical (cell and rodent), with no human data and integrity concerns over some original work, so its relevance to human clarity or protection is unestablished.

How they work together

Check this stack

Cerebrolysin and Cortexin work through almost the same idea — both are enzymatically digested animal-brain peptide mixtures acting as broad neurotrophic-factor mimics — so running them together is largely redundant rather than additive, and it becomes hard to attribute any benefit or side effect to one; most accounts suggest picking one. The synthetic peptides tend to pair complementarily because they reach shared endpoints by different routes: Dihexa's HGF/c-Met synaptogenesis complements the BDNF/NGF-TrkB signalling of Cerebrolysin, Cortexin, Noopept and Semax, all converging on PI3K/Akt survival and plasticity. Noopept and Semax, and Selank and Semax, are widely described real-world nootropic pairings — Selank calming while Semax is stimulating, so one smooths the other. Pinealon is reported as complementary and safe alongside Cerebrolysin and Semax through its distinct proposed gene-regulatory mechanism. Where combinations are noted as synergistic, that is mechanistic reasoning and anecdote; human combination trials are lacking.

  • Cerebrolysin + Cortexin

    Worth caution — see why below

    Both are enzymatically-digested animal-brain peptide mixtures (bovine/porcine cortex) working as broad neurotrophic-factor mimics — anti-apoptotic, anti-excitotoxic, anti-inflammatory, and pro-neuroplasticity. Because they occupy almost the same conceptual niche, running both together is largely redundant rather than additive, and it becomes impossible to tell which product is responsible for any benefit or side effect. Most users should pick one crude neurotrophic mixture rather than stack the two.

  • Cerebrolysin + Dihexa

    May be complementary

    Cerebrolysin supplies broad neurotrophic-factor mimicry (TrkA/TrkB, BDNF/IGF-1) while Dihexa amplifies HGF/c-Met-driven synaptogenesis. Different upstream mechanisms both feeding PI3K/Akt survival and plasticity signaling, so they can reinforce each other for neuroprotection and cognition.

  • Cerebrolysin + Noopept

    May be complementary

    Noopept raises BDNF/NGF, activates TrkB, and provides antioxidant/anti-inflammatory neuroprotection, echoing Cerebrolysin's neurotrophic and mitochondrial-support actions through a distinct dipeptide mechanism. The two can reinforce cognitive and neuroprotective signaling; combination evidence is anecdotal.

  • Cerebrolysin + Semax

    May be complementary

    Both upregulate BDNF and act via TrkB, reduce neuroinflammation, and modulate dopaminergic tone, but Semax (an ACTH fragment) adds enkephalinase inhibition and its own neurotrophin induction. Different upstream triggers converging on the same neuroprotective/nootropic output make them a plausible complementary nootropic pair. Human combination data are lacking.

  • Cortexin + Dihexa

    May be complementary

    Cortexin provides BDNF/NGF-like neurotrophic support and synaptic plasticity through a polypeptide mixture, complementing Dihexa's targeted HGF/c-Met synaptogenesis. Distinct mechanisms converging on neuronal survival and cognition.

  • Cortexin + Noopept

    May be complementary

    Cortexin modulates AMPA/glutamate signaling and protects neurons from excitotoxicity, while Noopept positively modulates AMPA receptors and raises BDNF/NGF via its cycloprolylglycine metabolite. They act on overlapping glutamatergic/neurotrophic machinery through distinct entry points, making them a plausible complementary nootropic pairing.

  • Cortexin + Selank

    May be complementary

    Both influence GABAergic tone and neurotransmitter balance and support BDNF signaling, but by different routes — Cortexin protects against glutamate excitotoxicity and Selank adds anxiolytic GABA-A/serotonergic modulation plus enkephalinase inhibition. Together they cover both the neuroprotective and the calm/anxiolytic side of brain function.

  • Cortexin + Semax

    May be complementary

    Cortexin supports neuronal survival through anti-excitotoxic, anti-apoptotic and neurotrophic actions, while Semax (an ACTH fragment) drives BDNF/NGF-TrkB signaling and cognitive enhancement by a distinct mechanism. Both converge on neuroprotection, neurogenesis and improved memory/attention, so they can complement each other rather than overlap.

  • Dihexa + Noopept

    May be complementary

    Noopept boosts BDNF/NGF and modulates AMPA/TrkB signaling for cognition, whereas Dihexa uses the HGF/c-Met synaptogenic route. Different mechanisms aimed at the same memory-enhancement and neuroprotection endpoint.

  • Dihexa + Semax

    May be complementary

    Semax raises BDNF/NGF and activates TrkB, while Dihexa works through HGF/c-Met — two distinct routes to enhanced neuroplasticity and neuroprotection that converge on the same nootropic goal.

  • Noopept + Selank

    May be complementary

    Selank and Noopept both engage BDNF signaling and both report anxiolytic plus nootropic effects, but through distinct mechanisms — Selank via GABAergic/serotonergic modulation and enkephalinase inhibition, Noopept via AMPA/TrkB neurotrophic pathways. Their overlapping calming-plus-cognitive profiles are complementary and this combination is a well-known real-world nootropic pairing.

  • Noopept + Semax

    May be complementary

    Both are cognitive-enhancing peptides that raise BDNF/NGF and act through the TrkB neurotrophin pathway, but by different upstream routes — Noopept via its cycloprolylglycine metabolite modulating AMPA/TrkB, and Semax via ACTH-fragment neurotrophin signaling. They converge on the same goals (memory, attention, neuroprotection, anxiolysis) and are commonly used together in nootropic practice, making the pairing potentially additive rather than redundant.

  • Selank + Semax

    May be complementary

    Selank and Semax are sister Russian regulatory peptides that both raise BDNF/NGF and both inhibit enkephalinase (extending your own opioid peptides), yet they push in different directions: Selank is calming/anxiolytic while Semax is stimulating and pro-attention. Stacked, one tends to smooth out the over-activation of the other, which is why they are a widely used nootropic pairing.

  • Cerebrolysin + Pinealon

    No known conflict in the research

    Pinealon is a short bioregulator peptide reported to reduce neuronal oxidative stress and apoptosis and support dendritic/neuroplastic changes, overlapping with Cerebrolysin's neurogenic and neuroprotective goal via a different (proposed gene-regulatory) mechanism. Combination is anecdotal.

  • Cerebrolysin + Selank

    No known conflict in the research

    Selank supports BDNF signaling, modulates monoamines and adds GABAergic anxiolytic tone plus immunomodulation, complementing Cerebrolysin's neurotrophic and anti-inflammatory profile. A reasonable nootropic/anxiolytic pairing, though only anecdotally documented together.

  • Pinealon + Semax

    No known conflict in the research

    Both support neuroprotection and neurogenesis but by completely different mechanisms — Semax via BDNF/TrkB neurotrophin signaling and Pinealon via proposed direct gene/DNA regulation and antioxidant enzyme upregulation. Different upstream targets converging on neuronal survival make this a plausibly complementary neuroprotective pairing.

5 other pairings have no documented interaction in our data — that is not a safety clearance.
  • Cortexin + Pinealon
  • Dihexa + Pinealon
  • Dihexa + Selank
  • Noopept + Pinealon
  • Pinealon + Selank

Compounds we looked at and left out

These share some biology with this goal, so you may have seen them recommended for it. Here is what our own research says about each.

  • Argirelinematched on acetylcholine pathway

    Argireline is linked to acetylcholine pathway, but in this compound that activity is about reducing facial muscle contractions to soften expression lines.

    “By imitating this fragment, it is proposed to interfere with the machinery nerves use to release the chemical messenger (acetylcholine) that tells facial muscles to contract. The idea is that reducing these contractions softens the repeated creasing that forms expression lines, giving it a marketing reputation as a topical, needle-free alternative to Botox.”— from its own profile
  • Leuphasylmatched on acetylcholine pathway

    Leuphasyl is linked to acetylcholine pathway, but in this compound that activity is about facial wrinkle reduction.

    “it is reported to bind enkephalin/opioid receptors on the nerve side of the neuromuscular junction and dampen the release of acetylcholine, the signal that makes facial muscles contract. With less contraction of the muscles that create expression lines (such as around the eyebrows and eyes), sources report a reduction in the depth of expression wrinkles.”— from its own profile
  • SYN-AKEmatched on acetylcholine pathway

    SYN-AKE is linked to acetylcholine pathway, but in this compound that activity is about reducing facial wrinkles and expression lines.

    “designed to mimic Waglerin-1, a component of Temple Viper venom, in order to relax facial muscles and soften the appearance of expression wrinkles while still allowing normal expressions”— from its own profile
  • SNAP-8matched on acetylcholine pathway

    SNAP-8 is linked to acetylcholine pathway, but none of its 2 research claims address this goal.

  • Epithalonmatched on new brain-cell growth

    Epithalon is linked to new brain-cell growth, but in this compound that activity is about circadian rhythm regulation and aging.

    “Epithalon is a small synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a natural extract from the pineal gland. Researchers report that it can switch on telomerase — the enzyme that maintains the protective caps (telomeres) on chromosomes — by increasing production of the hTERT component, and that in lab-grown human cells this lengthened telomeres and let cells divide past their usual limit. It is also studied as a regulator of the body clock, appearing to help restore normal nighttime melatonin production and circadian rhythms, and it acts as an antioxidant.”— from its own profile
  • Oxytocinmatched on dopamine system

    Oxytocin is linked to dopamine system, but in this compound that activity is about social bonding, empathy, and stress reduction.

    “Its best-established action, per the Pitocin label, is stimulating rhythmic contractions of the uterine smooth muscle by raising intracellular calcium, an effect that becomes strong toward the end of pregnancy when uterine receptors are most abundant. Beyond the uterus, reviews describe oxytocin acting in the brain as a 'prosocial' signaling molecule linked to social recognition, bonding, trust, empathy, stress responses and anxiety, though human behavioral findings are mixed and often fail to confirm effects seen in animals.”— from its own profile
  • Bremelanotidematched on dopamine system

    Bremelanotide is linked to dopamine system, but in this compound that activity is about sexual desire and arousal.

    “It switches on melanocortin receptors (mainly MC4R, and also MC3R) in the hypothalamus, tuning brain circuits involved in sexual desire and arousal.”— from its own profile
  • Melanotan IImatched on dopamine system

    Melanotan II is linked to dopamine system, but in this compound that activity is about sexual arousal and tanning.

    “Because it also hits receptors in the brain, it can trigger erections and sexual desire, suppress appetite, and affect glands — effects that cannot be separated from the tanning effect because the peptide is non-selective.”— from its own profile

What we can't tell you yet

Across every compound here, direct evidence for improving focus and clarity in healthy people is thin: the human trials concentrate on dementia, stroke, developmental delay, anxiety or post-Covid impairment, and none demonstrates prevention of cognitive decline in a healthy brain. Dihexa and Pinealon have essentially no human efficacy data for this goal, and several documented compound pairings rest on mechanism and anecdote rather than combination studies.

Sources

Ordered as cited above.

  1. :: JCN :: Journal of Clinical Neurology(opens in a new tab)
    Tier 1Web · thejcn.com
  2. Cerebrolysin for vascular dementia.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  3. Cerebrolysin & Your Brain | Cognitive Vitality | Alzheimer's Drug Discovery Foundation(opens in a new tab)
    Tier 1Web · alzdiscovery.org
  4. Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children - MedCrave online(opens in a new tab)
    Tier 1Web · medcraveonline.com
  5. [Neuprotection of post-acute COVID-19 cognitive impairment].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  6. Neurotropic Effects of Cortexin on Models of Mental and ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  7. Semax and N Acetyl Semax-Amide: discovery, actions, safety, animal data, and development(opens in a new tab)
    Tier 2Web · hvm.bioflux.com.ro
  8. The Potential of the Peptide Drug Semax and Its Derivative for ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  9. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  10. Comparative studies of Noopept and piracetam in the ...(opens in a new tab)
    Tier 1Web · researchgate.net
  11. N-Phenylacetyl-L-prolylglycine ethyl ester(opens in a new tab)
    Tier 2Web · examine.com
  12. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  13. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia(opens in a new tab)
    Tier 1Web · researchgate.net
  14. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  15. The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  16. Effect of seabuckthorn seed protein and its arginine-enriched peptides on combating memory impairment in mice.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  17. [Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  18. [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  19. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  20. AngIV-Analog Dihexa Rescues Cognitive Impairment and ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  21. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov

This brief reports what published research says about these compounds. It is information, not medical advice, and not a recommendation to use anything described here. Evidence quality varies by compound and is labelled throughout. Talk to a qualified clinician before acting on any of it.

See something wrong or out of date on this page? Report it.